Teva Pharma (TEVA) / Mylan (MYL) Combo Unlikely, Says Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Goldman Sachs Comments on Mylan (MYL) Following Yesterday's Rumors (TEVA) (ABT)
October 3, 2014 8:04 AM EDTGoldman Sachs maintained Buy rating on Mylan (NASDAQ: MYL) with a price target of $60. Comments follow yesterday's M&A chatter. Analyst Jami Rubin noted that Mylan is at a competitive disadvantage given lower tax rates at peers Actavis plc (NYSE: ACT),Perrigo (NYSE:... More
Standpoint Research Downgrades Teva Pharma (TEVA) to Hold
October 2, 2014 11:15 AM EDTStandpoint Research downgraded Teva Pharma (NYSE: TEVA) from Buy to Hold.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $52.99 yesterday.
... More